Honggang Liu
Papers
1
Total Citations
53
H-Index
1
About
Dr. Honggang Liu is a leading oncologist and clinical researcher whose work centers on thoracic oncology, with a particular focus on advancing treatment strategies for non-small cell lung cancer (NSCLC). His most impactful contributions lie in the realm of neoadjuvant immunotherapy, where he has pioneered the integration of PD-1 inhibitors with chemotherapy prior to surgical resection. Dr. Liu’s landmark 2021 open-label, multicenter, single-arm study, which has garnered over 50 citations, demonstrated that combining a PD-1 inhibitor with chemotherapy significantly improves pathological responses in resectable NSCLC. This work builds upon the foundational CheckMate 159 trial, extending the promise of single-agent nivolumab to more effective combination regimens. By showing that this neoadjuvant approach can enhance tumor shrinkage and potentially improve long-term survival outcomes, Dr. Liu has helped reshape perioperative treatment paradigms. His research is instrumental in moving the field toward more personalized, immunotherapy-based protocols for early-stage lung cancer. For students and researchers, Dr. Liu’s work exemplifies how rigorous clinical trial design can translate immunology breakthroughs into tangible patient benefits, marking him as a key figure in the evolution of lung cancer care.
Research Focus
Key Achievements
Top Papers
- 1